| Schedule of segments |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | | Diagnostics | | Therapeutic
Devices | | Development
Services | | Consolidated | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Net revenue | | $ | 1,625 | | $ | 762 | | $ | 7,169 | | $ | 6,671 | | $ | 1,105 | | $ | 662 | | $ | 9,899 | | $ | 8,095 | Cost of revenue | | | 719 | | | 616 | | | 2,568 | | | 1,793 | | | 568 | | | 250 | | | 3,855 | | | 2,659 | Gross profit | | $ | 906 | | $ | 146 | | $ | 4,601 | | $ | 4,878 | | $ | 537 | | $ | 412 | | $ | 6,044 | | $ | 5,436 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Nine Months Ended September 30, | | | Diagnostics | | Therapeutic
Devices | | Development
Services | | Consolidated | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | Net revenue | | $ | 3,976 | | $ | 2,102 | | $ | 19,744 | | $ | 18,795 | | $ | 4,490 | | $ | 662 | | $ | 28,210 | | $ | 21,559 | Cost of revenue | | | 1,936 | | | 1,762 | | | 6,599 | | | 5,038 | | | 2,106 | | | 250 | | | 10,641 | | | 7,050 | Gross profit | | $ | 2,040 | | $ | 340 | | $ | 13,145 | | $ | 13,757 | | $ | 2,384 | | $ | 412 | | $ | 17,569 | | $ | 14,509 |
|